Ait-Khaled M - Search Results

1

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.

Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM, Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM; VIKING-3 Study Group. Castagna A, et al. J Infect Dis. 2014 Aug 1;210(3):354-62. doi: 10.1093/infdis/jiu051. Epub 2014 Jan 19. J Infect Dis. 2014. PMID: 24446523 Free PMC article. Clinical Trial.

2

Intrapartum mucosal exposure to human immunodeficiency virus type 1 (HIV-1) of infants born to HIV-1-infected mothers correlates with maternal plasma virus burden.

Ait-Khaled M, Lyall EG, Stainsby C, Taylor GP, Wright A, Weber JN, McClure MO, Tudor-Williams G. Ait-Khaled M, et al. J Infect Dis. 1998 Apr;177(4):1097-100. doi: 10.1086/517403. J Infect Dis. 1998. PMID: 9534991

3

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.

Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Ait-Khaled M, Purdon S. Katlama C, et al. AIDS. 2000 May 5;14(7):781-9. doi: 10.1097/00002030-200005050-00003. AIDS. 2000. PMID: 10839585 Clinical Trial.

4

HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.

Falloon J, Ait-Khaled M, Thomas DA, Brosgart CL, Eron JJ Jr, Feinberg J, Flanigan TP, Hammer SM, Kraus PW, Murphy R, Torres R, Masur H; CNA2007 Study Team. Falloon J, et al. AIDS. 2002 Feb 15;16(3):387-96. doi: 10.1097/00002030-200202150-00010. AIDS. 2002. PMID: 11834950 Clinical Trial.

5

M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.

Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M; CNA3002 International Study Team. Ait-Khaled M, et al. AIDS. 2002 Aug 16;16(12):1686-9. doi: 10.1097/00002030-200208160-00017. AIDS. 2002. PMID: 12172093

6

Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial.

Pillay D, Walker AS, Gibb DM, de Rossi A, Kaye S, Ait-Khaled M, Muñoz-Fernandez M, Babiker A. Pillay D, et al. J Infect Dis. 2002 Sep 1;186(5):617-25. doi: 10.1086/342680. Epub 2002 Aug 9. J Infect Dis. 2002. PMID: 12195348 Clinical Trial.

7

Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.

Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V. Marcelin AG, et al. Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08. Epub 2008 Oct 13. Antimicrob Agents Chemother. 2008. PMID: 18852278 Free PMC article. Clinical Trial.

8

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects.

Brothers CH, Hernandez JE, Cutrell AG, Curtis L, Ait-Khaled M, Bowlin SJ, Hughes SH, Yeo JM, Lapierre DH. Brothers CH, et al. J Acquir Immune Defic Syndr. 2009 May 1;51(1):20-8. doi: 10.1097/QAI.0b013e31819ff0e6. J Acquir Immune Defic Syndr. 2009. PMID: 19282778

9

Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.

Molina JM, Ait-Khaled M, Rinaldi R, Penco G, Baril JG, Cauda R, Soriano V, Pialoux G, Wire MB, Lou Y, Givens N, Craig C, Nichols WG, Barbosa I, Yeo J; TRIAD Study Group. Molina JM, et al. J Antimicrob Chemother. 2009 Aug;64(2):398-410. doi: 10.1093/jac/dkp198. Epub 2009 Jun 10. J Antimicrob Chemother. 2009. PMID: 19515730 Clinical Trial.

10

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.

Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J; VIKING Study Group. Eron JJ, et al. J Infect Dis. 2013 Mar 1;207(5):740-8. doi: 10.1093/infdis/jis750. Epub 2012 Dec 7. J Infect Dis. 2013. PMID: 23225901 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters